- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy for Non-melanoma Skin Cancer
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 23, Issue 11, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-27
DOI
10.1007/s11912-021-01120-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-world assessment of response to anti-PD-1 therapy in advanced cutaneous squamous cell carcinoma
- (2021) Sophia Z. Shalhout et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
- (2020) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome
- (2020) Cuong V. Nguyen et al. JAMA Dermatology
- Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas
- (2020) Eve Maubec et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
- (2020) Jean-Jacques Grob et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
- (2020) Glenn J. Hanna et al. BRITISH JOURNAL OF CANCER
- Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment
- (2020) Michael R. Sargen et al. CLINICAL CANCER RESEARCH
- Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
- (2020) Martin Salzmann et al. EUROPEAN JOURNAL OF CANCER
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
- (2019) Paul Nghiem et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas
- (2019) Lucie Duverger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.
- (2019) Alexander David Guminski et al. JOURNAL OF CLINICAL ONCOLOGY
- Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab
- (2019) Brooke C. Bloom et al. Frontiers in Oncology
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Complete response with neoadjuvant avelumab in Merkel cell carcinoma – A case report
- (2019) Nadine Abdallah et al. ORAL ONCOLOGY
- Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
- (2019) Jaclyn LoPiccolo et al. Journal for ImmunoTherapy of Cancer
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
- (2019) et al. JAMA Oncology
- LBA74Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
- (2019) N Gross et al. ANNALS OF ONCOLOGY
- Effective anti-programmed death-1 therapy in a SUFU -mutated patient with Gorlin-Goltz syndrome
- (2018) A. Moreira et al. BRITISH JOURNAL OF DERMATOLOGY
- Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients
- (2018) Young Kwang Chae et al. CANCER TREATMENT REVIEWS
- Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
- (2018) Christopher K. Bichakjian et al. Journal of the National Comprehensive Cancer Network
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
- (2018) Stefanie Fischer et al. Oncology Research and Treatment
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma
- (2018) Sandra P. D’Angelo et al. JAMA Oncology
- Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
- (2018) Evidio Domingo-Musibay et al. Journal for ImmunoTherapy of Cancer
- Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
- (2018) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab
- (2018) Alessandra Chen et al. Journal of Clinical Medicine
- Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy
- (2018) Masood Sadaat et al. Journal of Oncology Practice
- Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.
- (2018) Jürgen C. Becker et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.
- (2018) Taofeek Kunle Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study
- (2018) Anne Lynn S. Chang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma
- (2018) Thomas J. Kandl et al. OncoImmunology
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
- (2017) Philip Cohen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy
- (2017) Fiona Day et al. JOURNAL OF IMMUNOTHERAPY
- Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
- (2017) J.T. Lear et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma
- (2017) Duy C. Tran et al. JAMA Dermatology
- Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
- (2017) Evan J. Lipson et al. Journal for ImmunoTherapy of Cancer
- Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases
- (2016) L. Borradori et al. BRITISH JOURNAL OF DERMATOLOGY
- Anti-programmed cell death-1 therapy in nonmelanoma skin cancer
- (2016) J.K. Winkler et al. BRITISH JOURNAL OF DERMATOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
- (2016) Evan J. Lipson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
- (2016) Gerald S. Falchook et al. Journal for ImmunoTherapy of Cancer
- Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
- (2016) Sadakatsu Ikeda et al. npj Genomic Medicine
- Risk Stratification for Rejection and Infection after Kidney Transplantation
- (2015) P. E. Cippa et al. Clinical Journal of the American Society of Nephrology
- Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC
- (2015) Aleksandar Sekulic et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir–Torre variant of Lynch syndrome
- (2014) Maegan E. Roberts et al. GENETICS IN MEDICINE
- Screening for Germline Mismatch Repair Mutations Following Diagnosis of Sebaceous Neoplasm
- (2014) Jessica N. Everett et al. JAMA Dermatology
- Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012
- (2013) Pritesh S. Karia et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Screening for Muir-Torre Syndrome Using Mismatch Repair Protein Immunohistochemistry of Sebaceous Neoplasms
- (2012) Maegan E. Roberts et al. Journal of Genetic Counseling
- Rare Tumors Through the Looking Glass
- (2011) Steve R. Martinez ARCHIVES OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search